17-ALLYL-4,5A-EPOXY-3,14-DIHYDROXYMORPHINAN-6-ONE
Mycosis Fungoides
Elorac, Inc.Small moleculePhase 3Dormant
B
57/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 45/ 100
- Competitive Position
- 81/ 100
Competitive context
51 Active assets in the Mycosis Fungoides cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
(+)-VINCRISTINE Virogen Biotechnology Inc. | Phase 4 | BBB |
Cyclophosphamide National Cancer Institute (NCI) | Phase 4 | BBB |
Fludarabine National Cancer Institute (NCI) | Phase 2 | BBB |
FILGRASTIM Mayo Clinic | Phase 4 | BBB |
METHOTREXATE Polish Lymphoma Research Group | Phase 4 | BBB |
View all 50 →
Same molecule, other indications
17-ALLYL-4,5A-EPOXY-3,14-DIHYDROXYMORPHINAN-6-ONE is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →